Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

Key Inclusion Criteria:

1. Men or women ≥50 years of age with active subfoveal CNV secondary to AMD, including
juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye as
assessed by a central reading center

2. BCVA ETDRS letter score of 73 to 24 (Snellen equivalent of 20/40 to 20/320) in the
study eye.

3. Willing and able to comply with clinic visits and study-related procedures.

4. Provide signed informed consent.

Key Exclusion Criteria:

1. Evidence of CNV due to any cause other than AMD in either eye

2. Prior IVT anti-VEGF in the study eye

3. Evidence of DME or diabetic retinopathy (defined as more than 1 microaneurysm) in
either eye in diabetic patients

4. Any history of macular hole of stage 2 and above in the study eye